KR101465275B1 - 11-베타-ｈｓｄ１ 억제제로서의 피리딘 카르복스아미드 - Google Patents

11-베타-ｈｓｄ１ 억제제로서의 피리딘 카르복스아미드 Download PDF

Info

Publication number
KR101465275B1
KR101465275B1 KR1020097010339A KR20097010339A KR101465275B1 KR 101465275 B1 KR101465275 B1 KR 101465275B1 KR 1020097010339 A KR1020097010339 A KR 1020097010339A KR 20097010339 A KR20097010339 A KR 20097010339A KR 101465275 B1 KR101465275 B1 KR 101465275B1
Authority
KR
South Korea
Prior art keywords
pyridin
acetic acid
piperidyl
propylsulfanyl
cyclohexylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097010339A
Other languages
English (en)
Korean (ko)
Other versions
KR20090075865A (ko
Inventor
윌리암 므코울
마틴 파커
제임스 스튜어트 스코트
폴 로버트 오웬 윗타모어
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20090075865A publication Critical patent/KR20090075865A/ko
Application granted granted Critical
Publication of KR101465275B1 publication Critical patent/KR101465275B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020097010339A 2006-11-03 2007-10-31 11-베타-ｈｓｄ１ 억제제로서의 피리딘 카르복스아미드 Active KR101465275B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86430306P 2006-11-03 2006-11-03
US86424706P 2006-11-03 2006-11-03
US60/864,247 2006-11-03
US60/864,303 2006-11-03
PCT/GB2007/004131 WO2008053194A2 (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors

Publications (2)

Publication Number Publication Date
KR20090075865A KR20090075865A (ko) 2009-07-09
KR101465275B1 true KR101465275B1 (ko) 2014-11-27

Family

ID=39304797

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097010339A Active KR101465275B1 (ko) 2006-11-03 2007-10-31 11-베타-ｈｓｄ１ 억제제로서의 피리딘 카르복스아미드

Country Status (30)

Country Link
US (3) US7964618B2 (enExample)
EP (2) EP2233480B1 (enExample)
JP (1) JP5165688B2 (enExample)
KR (1) KR101465275B1 (enExample)
CN (3) CN102603711A (enExample)
AR (1) AR063458A1 (enExample)
AT (1) ATE475649T1 (enExample)
AU (1) AU2007315955B2 (enExample)
BR (1) BRPI0717970C1 (enExample)
CA (1) CA2668006C (enExample)
CL (1) CL2007003176A1 (enExample)
CO (1) CO6321130A2 (enExample)
CY (1) CY1110813T1 (enExample)
DE (1) DE602007008137D1 (enExample)
DK (1) DK2086939T3 (enExample)
ES (2) ES2347491T3 (enExample)
HR (1) HRP20100522T1 (enExample)
IL (1) IL198231A0 (enExample)
MX (1) MX2009004707A (enExample)
NO (1) NO20091603L (enExample)
NZ (1) NZ576501A (enExample)
PE (1) PE20081487A1 (enExample)
PL (1) PL2086939T3 (enExample)
PT (1) PT2086939E (enExample)
RS (1) RS51451B (enExample)
RU (1) RU2451674C2 (enExample)
SI (1) SI2086939T1 (enExample)
TW (1) TW200827346A (enExample)
UY (1) UY30681A1 (enExample)
WO (1) WO2008053194A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618885A8 (pt) 2005-11-21 2018-06-26 Shionogi & Co compostos heterocíclicos tendo atividade inibitória de 11beta-hidroxiesteroide deidrogenase tipo i
TW200827346A (en) * 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
BRPI0811191A2 (pt) 2007-05-18 2014-10-29 Shionogi & Co Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009051112A1 (ja) * 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
WO2009056881A1 (en) * 2007-10-29 2009-05-07 Astrazeneca Ab Chemical compounds 313
RU2010133483A (ru) * 2008-02-04 2012-03-20 Астразенека Аб (Se) Новые кристаллические формы 4-{4-(2-адамантилкарбамоил)-5-третбутилпиразол-1-ил}бензойной кислоты
CA2719936A1 (en) * 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
JP2012529535A (ja) 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
UY32954A (es) * 2009-10-20 2011-05-31 Astrazeneca Ab PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
MX2012006022A (es) * 2009-11-24 2012-08-15 Allergan Inc Compuestos novedosos como moduladores de receptor con utilidad terapeutica.
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
BR122014023207A2 (pt) 2010-09-23 2019-05-28 Abbvie Inc. Compostos derivados de aza-adamantano, seus usos e processos para a preparação destes compostos
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
EP2735567B1 (en) * 2011-07-21 2016-10-26 Xuanzhu Pharma Co., Ltd. Heterocyclic substituted pyrimidine compound
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102659657B (zh) * 2012-04-24 2014-08-06 徐州医学院 一种蛋白酶抑制剂pf429242的合成方法
JP2015520202A (ja) 2012-06-20 2015-07-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｐａｒ拮抗薬としてのｎ−アルキルトリアゾール化合物
CA2869602A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Substituted pyrazole compounds as lpar antagonists
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
GB202216324D0 (en) * 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089896A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
WO2005054200A1 (en) 2003-11-29 2005-06-16 Astrazeneca Ab Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (enExample) 1978-02-21 1981-03-27 Delalande Sa
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
HU225917B1 (en) 1999-09-16 2007-12-28 Tanabe Seiyaku Co Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
DK1383731T3 (da) 2000-10-20 2009-12-07 Biocryst Pharm Inc Biarylforbindelser som serinproteaseinhibitorer
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2003217046A1 (en) 2002-04-05 2003-10-27 The University Of Edinburgh Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
SE0300458D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300457D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
UA81468C2 (en) 2003-02-26 2008-01-10 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives
AU2004265299B2 (en) 2003-08-07 2008-05-01 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
EA200600990A1 (ru) 2003-12-19 2006-10-27 Пфайзер Инк. Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
DE602005009500D1 (de) 2004-02-24 2008-10-16 Glaxo Group Ltd Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
CA2561791A1 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds
MXPA06012831A (es) 2004-05-06 2007-01-26 Pfizer Nuevos compuestos de derivados de morfolina y prolina.
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
WO2006000371A2 (en) 2004-06-28 2006-01-05 F.Hoffmann-La Roche Ag Pyrimidine derivatives as 11beta-hsd1 inhibitors
JP2008518903A (ja) 2004-11-02 2008-06-05 ファイザー・インク 置換および非置換アダマンチルアミドの新規化合物
EP1809290A2 (en) 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
KR101496206B1 (ko) 2005-01-05 2015-02-27 애브비 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
AU2006232660B2 (en) 2005-04-05 2010-03-25 F. Hoffmann-La Roche Ag 1H-Pyrazole 4-Carboxylamides, their preparation and their use as 11Beta-hydroxysteroid dehydrogenase
AU2006232662B2 (en) 2005-04-06 2011-11-24 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as CB1 inverse agonists
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US20110059941A1 (en) 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200716576A (en) 2005-06-07 2007-05-01 Shionogi & Co Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006132436A1 (ja) 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物
ES2334518T3 (es) 2005-06-16 2010-03-11 Pfizer, Inc. Derivados de n-(piridin-2-il)-sulfonamida.
BRPI0622261A2 (pt) 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
EP1915367A1 (en) 2005-08-09 2008-04-30 AstraZeneca AB Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
JP2009513711A (ja) 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ピロロン
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
BRPI0618885A8 (pt) 2005-11-21 2018-06-26 Shionogi & Co compostos heterocíclicos tendo atividade inibitória de 11beta-hidroxiesteroide deidrogenase tipo i
US20070197530A1 (en) 2006-01-31 2007-08-23 Yun-Long Li Amido compounds and their use as pharmaceuticals
AU2007228887B2 (en) 2006-03-22 2012-02-02 F. Hoffmann-La Roche Ag Pyrazoles as 11-beta-HSD-1
US8053447B2 (en) 2006-04-07 2011-11-08 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
EP2012775A1 (en) 2006-04-27 2009-01-14 Solvay Pharmaceuticals GmbH Use of cbx cannabinoid receptor modulators as potassium channel modulators
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
BRPI0811191A2 (pt) 2007-05-18 2014-10-29 Shionogi & Co Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1
EP2178845B1 (en) 2007-07-17 2013-06-19 F. Hoffmann-La Roche AG Inhibitors of 11b-hydroxysteroid dehydrogenase
CA2703781A1 (en) * 2007-11-06 2009-05-14 Astrazeneca Ab 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465
RU2010133483A (ru) * 2008-02-04 2012-03-20 Астразенека Аб (Se) Новые кристаллические формы 4-{4-(2-адамантилкарбамоил)-5-третбутилпиразол-1-ил}бензойной кислоты
CA2719936A1 (en) 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
EP2391607A1 (en) 2009-01-30 2011-12-07 AstraZeneca AB Novel process for preparing carboxy-containing pyrazoleamido compounds 597
UY32954A (es) * 2009-10-20 2011-05-31 Astrazeneca Ab PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089896A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
WO2005054200A1 (en) 2003-11-29 2005-06-16 Astrazeneca Ab Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators

Also Published As

Publication number Publication date
MX2009004707A (es) 2009-05-15
EP2233480A1 (en) 2010-09-29
NZ576501A (en) 2011-03-31
US20090312372A1 (en) 2009-12-17
CA2668006C (en) 2016-05-24
SI2086939T1 (sl) 2010-10-29
BRPI0717970B8 (pt) 2020-12-01
RU2451674C2 (ru) 2012-05-27
CA2668006A1 (en) 2008-05-08
PL2086939T3 (pl) 2011-09-30
AU2007315955B2 (en) 2011-04-14
CN101787016B (zh) 2013-08-28
CN102603711A (zh) 2012-07-25
EP2086939A2 (en) 2009-08-12
RU2009115830A (ru) 2010-12-10
HRP20100522T1 (hr) 2010-11-30
WO2008053194A2 (en) 2008-05-08
CN101787016A (zh) 2010-07-28
NO20091603L (no) 2009-05-28
CO6321130A2 (es) 2011-09-20
CY1110813T1 (el) 2015-06-10
PE20081487A1 (es) 2009-01-11
HK1135090A1 (en) 2010-05-28
DK2086939T3 (da) 2010-10-11
BRPI0717970A2 (pt) 2013-11-05
KR20090075865A (ko) 2009-07-09
ES2423206T3 (es) 2013-09-18
EP2086939B8 (en) 2011-06-22
JP2010508338A (ja) 2010-03-18
AU2007315955A1 (en) 2008-05-08
IL198231A0 (en) 2009-12-24
UY30681A1 (es) 2008-07-03
EP2086939B1 (en) 2010-07-28
BRPI0717970B1 (pt) 2019-10-22
CL2007003176A1 (es) 2008-07-25
DE602007008137D1 (en) 2010-09-09
US7964618B2 (en) 2011-06-21
CN101573336B (zh) 2012-03-21
TW200827346A (en) 2008-07-01
AR063458A1 (es) 2009-01-28
RS51451B (sr) 2011-04-30
WO2008053194A3 (en) 2008-10-02
US8673938B2 (en) 2014-03-18
JP5165688B2 (ja) 2013-03-21
BRPI0717970C1 (pt) 2021-05-25
ATE475649T1 (de) 2010-08-15
PT2086939E (pt) 2010-09-17
EP2233480B1 (en) 2013-05-29
ES2347491T3 (es) 2010-10-29
US20080269288A1 (en) 2008-10-30
US20090306075A1 (en) 2009-12-10
CN101573336A (zh) 2009-11-04

Similar Documents

Publication Publication Date Title
KR101465275B1 (ko) 11-베타-ｈｓｄ１ 억제제로서의 피리딘 카르복스아미드
CN103429585B (zh) 作为白细胞介素-1受体相关激酶抑制剂的吲唑基三唑衍生物
CA3162364A1 (en) Protein tyrosine phosphatase degraders and methods of use thereof
EP3426243B1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
KR20110002475A (ko) 치환 피리미딘-5-카르복시아미드 281
KR20090094026A (ko) Ｆｇｆｒ 억제제로서의 아실아미노피라졸
KR20050087832A (ko) Ｃｃｒ5 길항제로서 피페리딘 유도체
EP2721016A1 (en) Trpv4 antagonists
JP2016539146A (ja) 癌治療のためのｆａｓｎ阻害剤として有用なベンズアミド誘導体
CA2955062A1 (en) Novel 2,5-substituted pyrimidines as pde inhibitors
US20080200448A1 (en) New Pyridine Analogues VIII 518
HK1135090B (en) Pyridine carboxamides as 11-beta-hsd1 inhibitors
SA07280596B1 (ar) مركبات بيريدين الأميد وأستخدامها كمثبطات إنزيم β-11 هيدروكسى ستيرويد ديهيدروجينيز من النوع الأول
HK1191938B (en) Indazolyl triazole derivatives as irak inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090520

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20121030

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131213

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20141024

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20141119

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20141119

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20171018

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20171018

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20181018

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20181018

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20191016

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20191016

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20201015

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20211015

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20221017

Start annual number: 9

End annual number: 9